home technology partnering analytical services contacts

News

Glykos attends World ADC Europe Digital 8 – 11 March, 2021. Together with Genovis AB, Glykos presens a poster titled: Site-specific Antibody Drug Conjugation with 2-step Cleavable linker-payloads Displays Potent in-vivo Efficacy. In the poster, site-specific conjugation with Genovis’ GlyCLICK® technology and generation of unique ADCs using a glycopeptide linker with potent MMAE and PNU payloads was demonstrated. The resulting ADCs had DAR=2.0 and showed potent tumor killing activities in vitro and in vivo. See conference website for more information: https://worldadc-europe.com/.

December 10, 2020: Genovis and Glykos partner to enable new ADC platform
Thu, Dec 10, 2020 15:29 CET

Genovis AB and Glykos Finland Oy have today entered into a licensing and supply agreement for state-of-the-art linker-payload technologies to be combined with the site-specific antibody conjugation platform offered by Genovis.

By using GlyCLICK®, a site-specific antibody conjugationtechnology from Genovis and the latest novel linker and cytotoxic drug derivatives from Glykos, Genovis will offer biopharma customers a platform to screen and develop Antibody Drug Conjugates (ADCs) with improved performance. The partnership between Genovis and Glykos will enable scientists around the world to build ADCs from any off-the-shelf antibody, resulting in highly defined end products.

  • With Glykos unique linker and payload technologies, we can now offer the biopharma community a platform to rapidly transform any antibody into an advanced site-specific antibody drug conjugate. This enables our customers to explore new ways to develop ADCs which further broaden our market offering, says Fredrik Olsson CEO of Genovis.
  • With Genovis industry leading antibody processing enzymes and the GlyCLICK® platform, collaboration with Genovis opens new user base to our linker-payload ADC technologies. The combined product enables scientists to efficiently generate ADCs from their pipeline antibodies and to assess their functionality as unique research tools and potential therapeutics, says Juhani Saarinen CEO of Glykos.

The new GlyCLICK ADC products are available for purchase globally today through Genovis and distributors.
For more information visit: https://www.genovis.com/applications/adc-development/

More about ADC

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating primarily cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.

More about GlyCLICK®

The antibody conjugation technology GlyCLICK continues to show steady uptake in a range of markets and applications. One such application is the generation of site-specific antibody drug conjugates with defined number of drug molecules per antibody. The GlyCLICK technology encompasses enzymatic remodeling of the Fc-glycans and click-chemistry to ensure site-specific conjugation of antibodies.

About Glykos

Glykos’ business concept is to apply its technologies to provide state-of-the-art ADCs for clinical development. Today Glykos collaborates with pharmaceutical industry clients to advance novel ADCs towards the clinic. Glykos ADC technology platform includes glycoconjugation, stabilized maleimide conjugation, hydrophilic linkers for enhanced pharmacokinetics and novel high-potency payloads with improved therapeutic index. Glykos provides a full technology platform that enables development of superior ADC products in a very short development timeframe. For more information visit www.glykos.fi.

For more information, please contact: Juhani Saarinen, CEO, Glykos Finland Ltd. juhani.saarinen@glykos.fi

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.
The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Growth Market.